Continuing Medical Education Information

 

AACE Endocrine University

EU Y2 Event start date: 11/16/2023
Credit claim deadline: 12/31/2023

 

Statement of Need

Endocrine University® is designed to provide a forum for endocrinology fellows -in-training to enhance their endocrine curriculum, particularly in diabetes, thyroid, bone, and new technology which has become essential to the practice of endocrinology.

 

Target Audience

This program is intended for final year endocrine Fellows-in-Training.

 

Learning Objectives

By the end of the meeting, participants will be able to:

  • Effectively utilize new diagnostic technology that has become essential to the practice of endocrinology.
  • Apply the most up-to-date guidelines and evidence-based practices for the diagnosis and treatment of endocrine-related disorders.
  • Integrate the latest evidence-based research for diagnosis and treatment of emerging areas of endocrine-related practice.

 

Accreditation and Designation Statements

ACCME

The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Endocrinology (ACE) designates this other (live virtual) activity for a maximum of 18.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Disclosure and Conflicts of Interest Policy

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

 

Commercial Supporters

This activity is supported by educational grants from the following:

  • Abbott Diabetes Care
  • Novo Nordisk
  • Recordati Rare Diseases
  • Corcept Therapeutics
  • Lilly USA, LLC
  • Lilly USA, LLC
  • Dexcom, Inc.
  • Sandoz, Inc.
  • Merck-Pfizer Diabetes Collaboration
  • Amgen
  • Ultragenyx Pharmaceutical
  • Rhythm Pharmaceuticals

 

Planners

Planner Name

Sara E. Lubitz, MD, FACE

Ineligible Company

Hologic
Eli Lilly
Takeda
Amryt

Relevant Financial Relationship

Stock Ownership
Stock Ownership
Site PI Research Funding
Site PI Research Funding


Planner Name

Matthew J. Levine, MD, FACE

Ineligible Company

Abbott Laboratories
Mannkind
Novo Nordisk

Relevant Financial Relationship

Consultant
Speakers Bureau, Honoraria


All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

 

Faculty Disclosures

Faculty Name

Ejigayehu Abate, MD

Ineligible Company

Ascendis

Relevant Financial Relationship

Speakers Bureau, Consultant


Faculty Name

Brandi Addison, DO, FACE

Ineligible Company

Corcept
Eli Lilly
Novo Nordisk

Relevant Financial Relationship

Speakers Bureau
Speakers Bureau, Consultant
Speakers Bureau


Faculty Name

Robert Adler, MD

Ineligible Company

Radius Health

Relevant Financial Relationship

Research Funding to Institution


Faculty Name

Caroline Apovian, MD

Ineligible Company

Abbott Nutrition
Allergan, Inc
Altimmune, Inc
Cowen and Company, LLC
Curavit Clinical Research
EnteroMedics
Gelesis
Jazz Pharmaceuticals, Inc
L-Nutra, Inc
NeuroBo Pharmaceuticals
NIH
Novo Nordisk
Pain Script Corporation
PCORI
Real Appeal
Rhythm Pharmaceuticals
Riverview School
Roman Health Ventures, Inc
Scientific Intake Ltd. Co.
Tivity Health, Inc.
Xeno Biosciences
Zafgan Inc.

Relevant Financial Relationship

Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Research Funding
Research Funding, Advisory Board
Advisory Board
Research Funding
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board


Faculty Name

Richard J. Auchus, MD, PhD, FACE

Ineligible Company

Adrenas Therapeutics
Corcept
Crinetics
Diurnal, LTD
H Lundbeck A/S
Janssen Pharmaceuticals
Neurocrine Biosciences
Novartis Pharmaceuticals
Novo Nordisk
OMass Therapeutics
PhaseBio Pharmaceuticals
Quest Diagnostics
Recordati Rare Diseases
Spruce Biosciences
Sparrow Pharma
Takeda
Xeris

Relevant Financial Relationship

Consultant
Research Funding, Consultant
Consultant
Research Funding
Consultant
Consultant
Research Funding
Research Funding, Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Research Funding
Research Funding
Consultant
Consultant


Faculty Name

Irina Bancos, MD

Ineligible Company

Adrenas
Corcept
HRA Pharma
Diurnal
Neurocrine
Recordati
Sparrow
Spruce

Relevant Financial Relationship

Consultant
Consultant
Consultant
Consultant
Consultant
Consultant, Research Funding
Consultant
Consultant


Faculty Name

Shalender Bhasin, MD

Ineligible Company

AbbVie
Aditum
FPT
MIB
OPKO
Transition Therapeutics
Xyone

Relevant Financial Relationship

Stock Ownership, Research Funding
Stock Options, Consultant
Stock Ownership, Research Funding
Stock Ownership, Research Funding
Stock Ownership
Stock Ownership, Research Funding
Stock Ownership


Faculty Name

Dan Bessesen, MD

Ineligible Company

Eli Lilly
Novo Nordisk

Relevant Financial Relationship

Stock Options
Stock Options


Faculty Name

John Carmichael, MD

Ineligible Company

Chiasma
Camurus Acromegaly
Novo Nordisk
Recordati

Relevant Financial Relationship

Research Funding
Consultant
Consultant
Consultant


Faculty Name

Geetha Gopalakrishnan, MD, FACE

Ineligible Company

Medtronic
Sparrow and Spruce

Relevant Financial Relationship

Research Funding
Research Funding


Faculty Name

Amir Hamrahian, MD

Ineligible Company

Corcept
HRA Pharma
Xeris Pharmaceutical

Relevant Financial Relationship

Stock Ownership
Stock Ownership
Stock Ownership


Faculty Name

Betul Hatipoglu, MD

Ineligible Company

Noom App
Sparrow Pharma
Tandem

Relevant Financial Relationship

Research Funding
Research Funding
Stock Options


Faculty Name

Mimi Hu, MD

Ineligible Company

Eli Lilly
Medical Education Resources
Medullary Thyroid Cancer Consortium Registry
Nordisk
Astra Zeneca

Relevant Financial Relationship

Stock Options, Research Funding
Stock Options
Stock Options
Stock Options
Stock Options


Faculty Name

Adriana Ioachimescu, MD, PhD, FACE

Ineligible Company

Strongbrindge
Xeris Pharma
Chiasma
Amryt
Recordati
HRA Pharma
Camurus

Relevant Financial Relationship

Stock Ownership
Stock Ownership, Research Funding, Consultant
Stock Ownership
Stock Ownership, Research Funding, Consultant
Stock Ownership, Research Funding, Consultant
Consultant
Consultant


Faculty Name

Laurence Katznelson, MD

Ineligible Company

Ascendis
Camarus
Crinetics
Novo Nordisk
Recordati
Strongbridge

Relevant Financial Relationship

Research Funding
Research Funding, Consultant
Research Funding
Consultant
Consultant
Consultant


Faculty Name

Ann Kearns, MD

Ineligible Company

Amgen

Relevant Financial Relationship

Research Funding


Faculty Name

Jennifer Kelly, DO, FACE, CCD

Ineligible Company

Radius Pharma
Ascendis

Relevant Financial Relationship

Research Funding, Consultant
Research Funding, Consultant


Faculty Name

Steven Petak, MD, JD, MACE

Ineligible Company

Alexion
Amgen

Relevant Financial Relationship

Speakers Bureau
Speakers Bureau


Faculty Name

Susan Samson, MD, PhD, FRCPC, FACE

Ineligible Company

Chiasma/Amryt
Corcept

Relevant Financial Relationship

Stock Ownership
Stock Ownership


Faculty Name

Meera Shah, MB, ChB, MRCP

Ineligible Company

Pendulum Therapeutics

Relevant Financial Relationship

Research Funding


Faculty Name

Vinaya Simha, MD, MBBS

Ineligible Company

Pfizer

Relevant Financial Relationship

Consultant


Faculty Name

Arthi Thirumalai, MD, MBBS

Ineligible Company

Fractyl Laboratories
Novo Nordisk

Relevant Financial Relationship

Research Funding
Research Funding


Faculty Name

Dace Trence, MD, MACE

Ineligible Company

Medtronic
Sanofi

Relevant Financial Relationship

Stock Options
Stock Options


Faculty Name

Anand Vaidya, MD, MMSc

Ineligible Company

Corcept
HRA Pharma
Mineralys

Relevant Financial Relationship

Consultant
Consultant
Consultant


Faculty Name

Robert Wermers, MD, FACE

Ineligible Company

Alexion
Inozyme

Relevant Financial Relationship

Research Funding
Research Funding


Faculty Name

William F. Young, Jr., MD, FACP, FACE

Ineligible Company

Bayer AG
Crinetics

Relevant Financial Relationship

Stock Ownership
Stock Ownership


Faculty Name

Kevin Yuen, MD, FRCP, FACE

Ineligible Company

Amryt
Ascendis
Corcept
Crinetics
Ipsen
Novo Nordisk
Recordati
Rani Therapeutics
Strongbridge
Xeris Pharma

Relevant Financial Relationship

Research Funding, Consultant
Research Funding
Research Funding, Speakers Bureau
Research Funding, Consultant
Consultant
Speakers Bureau, Consultant
Speakers Bureau, Consultant
Consultant
Consultant
Consultant


Faculty Name

Mihail Zilbermint, MD, FACE

Ineligible Company

ROM Tech
EMD Serono

Relevant Financial Relationship

Stock Options
Consultant


All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

Reviewers

None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.